Literature DB >> 25979319

Glucose-6-Phosphate Dehydrogenase Screening in Israel-Arab and Palestinian-Arab Neonates.

Rawan Abu Omar1, Nurit Algur2, Orli Megged3, Cathy Hammerman4, Michael Kaplan5.   

Abstract

OBJECTIVE: To evaluate the frequency of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, the incidence of clinically significant jaundice (any serum total bilirubin value >75th percentile on the hour-specific bilirubin nomogram), and the need for phototherapy in the pooled male Israeli-Arab and Palestinian-Arab population born at the Shaare Zedek Medical Center in Jerusalem, Israel. STUDY
DESIGN: Quantitative G-6-PD enzyme testing of umbilical cord blood was performed during birth hospitalization. G-6-PD deficiency was defined as any G-6-PD value <7.0 U/gHb. Transcutaneous bilirubin was performed daily during birth hospitalization, with serum total bilirubin testing in those with a transcutaneous bilirubin value >75th percentile.
RESULTS: Ten of 286 (3.5%) consecutively delivered male Arab newborns had G-6-PD deficiency. Clinically significant jaundice was higher in the population with G-6-PD deficiency compared with normal controls (relative risk, 3.45; 95% CI, 1.24-9.58). Thirty percent of the newborns with G-6-PD deficiency met American Academy of Pediatrics indications for phototherapy according to the high-risk (middle) curve on the phototherapy graph.
CONCLUSION: The frequency of G-6-PD deficiency in the Arab neonatal population delivering at this medical center meets World Health Organization criteria for neonatal G-6-PD screening (3%-5%). As in other ethnic groups, clinically significant jaundice is more frequent in newborns of this ethnic group with G-6-PD deficiency compared with G-6-PD-normal controls. Neonatal G-6-PD screening for both males and females of this population subgroup, in conjunction with parental education regarding the dangers of the condition and its prophylaxis, has now been incorporated into our institution's routine G-6-PD screening program.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25979319     DOI: 10.1016/j.jpeds.2015.04.039

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Israel transcutaneous bilirubin nomogram predicts significant hyperbilirubinemia.

Authors:  R Bromiker; A Goldberg; M Kaplan
Journal:  J Perinatol       Date:  2017-08-31       Impact factor: 2.521

2.  Comparison of Spectrophotometric and Fluorimetric Methods in Evaluation of Biotinidase Deficiency.

Authors:  Sevgin Özlem Işeri-Erten; Zeliha Günnur Dikmen; Nuriye Nuray Ulusu
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.